Compare AbCellera Biologics Inc (ABCL) vs Vital Farms Inc (VITL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Vital Farms Inc — how do they compare? AbCellera Biologics Inc trades at $7.1 (market cap $2.35B), while Vital Farms Inc trades at $12.35 (market cap $563.24M). The key difference: AbCellera Biologics Inc is far larger — about 4.2× Vital Farms Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | VITL | |
|---|---|---|
Market Cap | $2.35B | $563.24M |
Sector | Health | Consumer Staples |
52-Week High | $8.12 | $52.41 |
52-Week Low | $2.78 | $8.28 |
Enterprise Value | $1.99B | $566.05M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Vital Farms (VITL) trades at $12.84, up 0.63% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported 2025 revenue of $759.44M and net income of $66.28M, though earnings have missed expectations in recent quarters. Analysts maintain a Buy consensus with a $14.00 price target, but negative cash flow and a class action lawsuit pose headwinds.
The stock offers value with a P/E of 12.35 and P/S of 0.75, but risks include declining profitability, legal challenges, and sustained negative cash flow. Upside depends on execution improvements and resolving litigation, while failure to stabilize earnings could pressure valuations further.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
